MedTrace Logo

A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

NCT03251924 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2023-02-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate BMS-986226 administered alone or in combination with nivolumab or ipilimumab.

Conditions

Interventions

DRUG

BMS-986226

specified dose on specified days

BIOLOGICAL

Nivolumab

specified dose on specified days

BIOLOGICAL

Ipilimumab

specified dose on specified days

BIOLOGICAL

Tetanus Vaccine

specified dose on specified days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-01
Primary Completion
2021-12-20
Completion
2021-12-20
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03251924 on ClinicalTrials.gov